Vurdon 

Quick links to important sections

Vurdon 

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vurdon 

What is Vurdon?

Vurdon is a medicinal product containing the active substance diclofenac sodium. It belongs to a group of medications known as non-steroidal anti-inflammatory drugs (NSAIDs). These agents are primarily used to manage symptoms associated with inflammation, pain, and fever.

Mechanism of Action

The active component, diclofenac, works by inhibiting the activity of enzymes called cyclooxygenases (COX-1 and COX-2). These enzymes are responsible for the production of prostaglandins, which are naturally occurring chemicals in the body that act as mediators of inflammation and pain signals. By reducing the synthesis of these substances, the medication helps to alleviate swelling and discomfort.

Therapeutic Applications

Vurdon is utilized for the symptomatic relief of various conditions characterized by pain and inflammation. Its applications typically include:

  • Inflammatory Rheumatic Diseases: Conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
  • Acute Musculoskeletal Disorders: Soft tissue injuries including sprains, strains, and sports-related injuries.
  • Other Painful Conditions: Management of acute attacks of gout, postoperative pain, and painful inflammatory conditions in non-rheumatic contexts.

While the medication effectively addresses the symptoms of inflammation and pain, it does not treat the underlying cause of the condition or provide a permanent cure for chronic diseases.

Regulatory References

  1. includes it on its Model List of Essential Medicines

What side effects are possible with Vurdon ?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Vurdon (Diclofenac) by classifying adverse reactions according to frequency and the body system affected, consistent with its designation as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on incidence observed in official sources:

  • Common Reactions (affecting 1 to 10 users in 100): These include gastrointestinal effects such as nausea, abdominal pain, dyspepsia, and flatulence. Effects on the nervous system, like headache and dizziness, as well as transient increases in liver enzymes (transaminases), are also listed as common.
  • Rare/Very Rare Reactions: These categories include serious adverse events, such as severe liver injury (hepatitis), severe hypersensitivity responses, and serious dermatological conditions.

Serious Safety Constraints and Adverse Events

Regulatory labels highlight risks of serious adverse reactions that can occur at any point during use:

  • Cardiovascular Thrombotic Events: A primary safety constraint is the potential for serious, sometimes fatal, cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with the duration of therapy and may occur early in treatment.
  • Gastrointestinal Complications: The risk of serious gastrointestinal adverse events, specifically bleeding, ulceration, and perforation, is documented. These can be fatal and may occur without prior symptoms.

Population and Duration-Specific Safety Notes

Safety statements include specific considerations for certain patient groups. Older patients are recognized as having an increased risk for serious gastrointestinal adverse events. Furthermore, Vurdon is contraindicated in the third trimester of pregnancy due to documented risks to the fetus. The medicine is also restricted for use in patients with established severe heart failure or immediately following coronary artery bypass graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Vurdon (Diclofenac) is documented in regulatory prescribing information, which focuses on the clinical manifestations and mandatory emergency actions. Overdose is commonly characterized by disturbances in the gastrointestinal and central nervous systems.

Classification Official Regulatory Status
Documented Manifestations Nausea, vomiting, epigastric pain, headache, drowsiness, dizziness, and tinnitus are frequently reported. Severe cases can include loss of consciousness.
Severe Outcomes Officially documented life-threatening risks include acute renal failure, liver damage, respiratory depression, and severe hypotension. Gastrointestinal bleeding and convulsions are also noted, particularly in children.
Antidote Status No specific antidote is known for Vurdon overdose, as confirmed in regulatory labeling.

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose, even if symptoms are mild or absent. Urgent help is required for severe signs such as seizures, profound low blood pressure, or evidence of gastrointestinal bleeding (e.g., bloody or black stools). Management, as described in official documents, is strictly symptomatic and supportive, focusing on mitigating potential complications and maintaining physiological stability. Hospital monitoring is required due to the risk of delayed severe effects.

Therapeutic Uses of Vurdon 

What Vurdon Treats: Main Uses and Benefits

Vurdon is commonly used to help with symptoms related to physical discomfort, inflammation, and fever. It offers supportive relief across key clinical domains where these manifestations create distress and interfere with function. Its application focuses solely on easing the overall symptom load to improve comfort and stability during difficult episodes.


This medication is applied in addressing chronic inflammatory conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also considered relevant for acute manifestations that create noticeable physiological strain in specific episodic syndromes, including gout flares, acute migraine attacks, and primary dysmenorrhea. The supportive relief is relevant when short-term symptomatic assistance is needed for pain and inflammation arising from minor strains, sprains, or postoperative discomfort.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Pain and Functional Strain

Vurdon contributes to assisting with functional stability in chronic joint conditions by addressing recurrent stiffness and swelling, which may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH LiverTox overview of Diclofenac's Uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Vurdon (Diclofenac)

The eligibility for Vurdon is strictly defined by regulatory documents, outlining populations that may use the medicine and those who are formally restricted or contraindicated.


Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Established for use in Adults and Adolescents (typically starting at 12 or 14 years, varying by formulation).
Populations for whom use is contraindicated Patients with known hypersensitivity to Diclofenac or other NSAIDs/Aspirin, or active Gastrointestinal Ulceration/Bleeding. Use is prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the last trimester of pregnancy (from 30 weeks gestation).
Condition-specific eligibility rules Contraindicated in established Severe Heart Failure (NYHA Class II-IV), Ischaemic Heart Disease, and severe Renal or Hepatic Failure.

Population-Specific Limitations

Limitation Regulatory Guidance
Age-related rules Elderly patients must use the lowest effective dose for the shortest duration. Use in children under 12 years is generally not established for many oral forms.
Restricted use Patients with Cardiovascular Risk Factors (e.g., hypertension) or a prior history of GI bleeding must use the medicine only after careful assessment and with caution.
Pregnancy/Lactation Contraindicated in the third trimester. Use is limited between 20 and 30 weeks gestation. Use while breastfeeding requires professional advice.

What should I know about interactions with other medicines?

Vurdon’s interaction profile is officially defined by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. The medicine is contraindicated for treating perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and must not be used by patients with a history of allergic reactions to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).


Documented Pharmacodynamic and Clearance Interactions

Co-administration with other NSAIDs, Anticoagulants (such as Warfarin), or SSRIs/SNRIs results in a synergistic increase in the risk of serious gastrointestinal adverse events. Furthermore, Vurdon can affect drug clearance. Regulatory documents note that it reduces the renal clearance of Lithium, potentially leading to elevated plasma levels, and it may competitively inhibit the renal accumulation of Methotrexate, which can enhance its toxicity.

Metabolic and Administration Constraints

A pharmacokinetic interaction is documented when Vurdon is combined with the potent CYP2C9 inhibitor, Voriconazole, leading to significantly increased systemic exposure (Cmax and AUC) of Vurdon. The official labeling for the Vurdon powder for oral solution formulation notes that co-administration with food may lead to a reduction in its overall effectiveness. Caution is also noted for combined use with ACE Inhibitors or ARBs, particularly in the elderly or those with renal impairment, due to the documented risk of acute renal function decline.

Mechanism of Action

How Vurdon Works

Enzyme-Mediated Prostanoid Synthesis Inhibition

Vurdon's primary pharmacodynamic mechanism involves inhibition of cyclooxygenase (COX) enzymes, specifically targeting COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid into signaling molecules known as prostanoids, including prostaglandins and thromboxanes. The competitive inhibition of COX activity directly suppresses the biosynthesis of these prostanoid mediators, resulting in the attenuation of downstream prostanoid-mediated signaling within cellular pathways.


️ Modulation of Local Signaling Cascades

Beyond COX inhibition, the drug modulates other local signaling pathways. The resultant reduced prostanoid concentration gradient establishes a diminished chemical signaling environment necessary for inflammatory cascade propagation. Furthermore, Vurdon influences the magnitude and duration of signaling within nociceptive pathways, potentially involving mediators such as L-arginine/nitric oxide/cGMP and substance P. This action is defined by a diminished molecular response to transmitter activity, modulating processes governed by these downstream signaling patterns.

Dosage and Administration Information

How to Use Vurdon (Diclofenac)

The administration of Vurdon is defined by the specific formulation, adhering to the principle of using the lowest effective dose for the shortest duration possible. The medicine is available for Oral (tablets, solution), Topical (gels, solutions), and Parenteral (intramuscular and intravenous) routes of administration.


Standard Dosing and Frequency

Oral dosing for chronic conditions is typically in divided doses two to four times daily. For instance, in Osteoarthritis, the daily dose generally ranges from 100 mg to 150 mg. For Rheumatoid Arthritis, the official daily maximum can be up to 225 mg, depending on the specific oral formulation used. For acute pain management, such as the intravenous (IV) bolus, the dose is 37.5 mg repeated up to every six hours, with a maximum of 150 mg per day.


Administration Conditions and Constraints

The timing of Vurdon intake varies by form. Delayed-release tablets may be taken with or without food. However, specific oral formulations, such as the powder for solution, must be taken on an empty stomach and mixed strictly with 30 to 60 mL of water, consumed immediately.

Special handling is required for certain forms: delayed-release tablets must be swallowed whole and must not be crushed, chewed, or split. For parenteral administration, patients must be well hydrated prior to receiving the dose. For elderly or frail patients, it is standard practice to start with the lowest effective dosage to maintain procedural consistency.

Recent Clinical Evidence

Vurdon : Recent Clinical Evidence

This section outlines the research evidence that has evaluated the use of Drug A (Vurdon ) in Chronic Pain Syndrome (CPS).


Clinical Trial Findings

Clinical trials examined participant reports of pain severity and frequency in participants with CPS. Research also collected data related to proposed mechanisms of action, and findings reported on overall pain scores.

  • Phase 1 & 2 Trials: Early studies primarily focused on establishing the pharmacokinetic profile and dose tolerability in small groups of volunteers and later, participants with CPS. These trials examined preliminary data on pain reporting.
  • Phase 3 Trials: Large-scale, randomized, placebo-controlled trials evaluated the use of Drug A compared to a placebo. A pivotal Phase 3 trial, known as the 'Relief' study, investigated the parameters of this treatment. One finding focused on participant reports of nighttime pain.

Results and Metrics Studied

Some studies noted that changes in pain scores were reported within the first week of treatment initiation.

  • Primary Endpoint: The primary endpoint in most pivotal studies was a ge 30% reduction in pain intensity from baseline, as measured by the Visual Analog Scale (VAS) or Numerical Rating Scale (NRS) at 12 weeks.
  • Secondary Endpoints: Secondary outcomes often included whether changes in sleep quality, daily analgesic use, and overall quality of life scores were observed.

Limitations and Gaps in Evidence

Evidence regarding the long-term (>1 year) outcomes following study participation with Drug A remains limited at this time. It is not yet clear whether Drug A has different outcomes in older adult populations (>65 years) versus younger adults, as sub-group analyses have produced mixed findings.

Key Studies & References

  1. Efficacy and Safety of Vurdon in Chronic Pain Syndrome: The Randomized, Double-Blind, Placebo-Controlled 'Relief' Study
  2. Guideline for the Management of Chronic Primary Pain in Adults: Assessment of Pharmacologic and Non-Pharmacologic Co-Interventions
  3. Phase 1 and 2 Clinical Trials: Pharmacokinetics and Dose Tolerability of Vurdon in Healthy Volunteers and Pain Patients

Frequently Asked Questions (FAQ)

Common questions about Vurdon  (FAQ)

Q: Why do some people say Vurdon made them feel tired?

Official documentation lists certain effects on the nervous system, such as dizziness and headache, as common adverse reactions. While 'tiredness' or 'fatigue' may not be explicitly listed, these common neurological effects are described in official information regarding the use of Vurdon.

Q: Can Vurdon be taken with common pain relievers like ibuprofen?

Vurdon belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class of medicines. Official guidelines typically advise against combined use with other NSAIDs, including common pain relievers like ibuprofen. This is due to a significantly increased risk of serious gastrointestinal issues, such as bleeding or ulcers.

Q: Is Vurdon the same as [common similar drug name]?

Vurdon contains the active ingredient Diclofenac, which classifies it as a Nonsteroidal Anti-inflammatory Drug (NSAID). This places it in the same large pharmacological class as many other widely used pain and inflammation medicines.

Q: Why does the official document mention avoiding [specific lifestyle factor]?

Official labeling indicates that certain specific oral formulations, such as the powder for solution, are intended to be taken on an empty stomach. The primary reason for this instruction is that taking that form with food can significantly reduce the overall effectiveness of the medicine.

Q: Were clinical trials for Vurdon conducted on a diverse group of people?

Clinical trial summaries indicate that studies have included analyses of various patient sub-populations, such as older adults (those over 65 years old). It is noted in research summaries that evidence regarding differential outcomes in older adults compared to younger adults remains mixed.

Q: How long does Vurdon stay in your system after stopping treatment?

Pharmacokinetic studies show that the terminal half-life of Vurdon in the blood is generally 1 to 2 hours. The effects of the medicine are generally understood to diminish around 15 hours after the last dose.

Q: How quickly does Vurdon start to work?

Clinical trial data has observed changes in pain scores reported by participants within the first week of beginning treatment. For localized preparations, such as topical gels, official sources indicate that a noticeable effect may be observed within 1 to 2 days.

Q: What is the typical timeframe for seeing the full effect of Vurdon?

In pivotal clinical trials, the full benefit is often measured using primary study endpoints. These endpoints, such as a substantial reduction in pain intensity, are commonly assessed at a specific period, such as 12 weeks following the start of treatment.

Q: Is Vurdon a long-term medication?

Regulatory guidelines describe its use as limited to the lowest effective dose for the shortest duration possible. It is not generally described as a medication for indefinite long-term use, especially considering the documented risks associated with prolonged use.

Q: Is Vurdon safe for older patients (senior citizens)?

Official safety documents advise that older patients are recognized as having an increased risk for serious gastrointestinal adverse events. Regulatory guidelines state that use in this population should be limited to the shortest duration possible.

Q: Does Vurdon affect appetite?

Common adverse reactions listed in official documents include gastrointestinal effects such as nausea, abdominal pain, and dyspepsia (indigestion). In rare cases, severe liver injury has been reported as being preceded by anorexia, which is the medical term for loss of appetite.

Q: Can I drive or operate machinery while taking Vurdon?

Official warnings state that Vurdon may cause adverse effects such as dizziness, vertigo, or visual disturbances. These effects could impair the ability to drive or safely operate complex machinery. The product labeling advises people to be aware of their reaction to the medicine.

Q: What is the typical treatment period with Vurdon?

The treatment duration varies based on the condition being treated, such as acute pain versus chronic inflammatory conditions. For chronic conditions, it is typically given in divided daily doses, but regulatory constraints always require the treatment to be limited to the shortest duration possible.

Q: Are there different strengths of Vurdon available?

Yes, official product labeling shows that various forms of Vurdon are supplied in different strengths. For example, oral delayed-release tablets are typically available in 25 mg, 50 mg, and 75 mg strengths, in addition to varying concentrations for gels or solutions.

Q: Does Vurdon affect fertility?

Official patient information notes that taking anti-inflammatory medicines like Vurdon at high doses or for a prolonged period may affect ovulation in women. This potential effect could make it more difficult for a person to conceive.

Q: Is it normal to have [mild, non-serious side effect] when starting Vurdon?

Official documentation categorizes side effects into frequency groups, listing 'Common Reactions' as those affecting 1 to 10 people in 100. This group includes gastrointestinal effects like nausea and headache, which are the most frequently reported side effects when starting the medicine.

Q: What happens if I miss a scheduled dose of Vurdon?

Instructions provided in patient information leaflets often advise that if you miss a dose, you should skip the missed dose if it is almost time for the next scheduled dose. Official patient information often advises against taking two doses together to compensate for a missed dose.

Q: Is Vurdon known to cause liver problems?

Official warnings note that Vurdon can cause an elevation of liver enzyme tests during therapy. Serious side effects, including severe liver injury (hepatitis), have been documented, and discontinuation is recommended if abnormal liver tests persist or worsen.

Q: How does Vurdon affect laboratory tests?

Regulatory documents specifically mention the potential for Vurdon to cause elevated serum aminotransferase levels, which are a specific type of liver function test. Monitoring of these laboratory tests is often recommended in official guidance during the course of treatment.

Q: Is Vurdon a controlled substance?

Vurdon's active ingredient, Diclofenac, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not listed as a scheduled narcotic or controlled substance by the major government drug enforcement or regulatory agencies.

Q: Does Vurdon work better if taken in the morning or evening?

While oral doses are generally divided throughout the day, certain formulations may have specific recommendations. For example, some topical (skin) formulations are explicitly recommended for use twice a day (preferably morning and evening) to maintain consistent absorption and effect.

Q: Can Vurdon make you gain or lose weight?

Official product information cites adverse effects such as fluid retention (edema) and potential risks to kidney function. These effects may be associated with changes in a person's body weight due to fluctuations in fluid status.

Q: What if I have an allergic reaction to Vurdon?

Vurdon is formally contraindicated for patients with a known hypersensitivity to the drug or other NSAIDs. If an allergic reaction occurs, official warnings recommend that the medicine be discontinued immediately.

Q: Does Vurdon help with [minor symptom related to condition]?

Official indications and regulatory documents state that Vurdon is approved for the general reduction of pain, inflammation, and fever. Its use is based on its core pharmacological actions to interrupt the body's processes that signal pain and swelling.

Q: Can Vurdon cause blurred vision?

Official regulatory documentation lists visual disturbances and blurred vision as potential adverse reactions. Patients who experience such symptoms are advised to report them, particularly if these visual changes are persistent.

Q: Is Vurdon the type of drug that needs to be gradually stopped?

For most standard uses, official instructions typically do not require the medicine to be gradually stopped. The effects are generally understood to diminish naturally within approximately 15 hours after a dose.

Q: Can Vurdon interact with herbal supplements?

Official patient information includes a general caution to inform your prescribing professional if you are taking any other medicines, including herbal supplements. This is because certain supplements may have overlapping effects or increase the potential for adverse events.

Q: Do you need a prescription for Vurdon?

Vurdon is available in various strengths and dosage forms. In many regulatory regions, certain oral doses and specialized forms are classified as prescription-only (Rx), while lower-strength topical gels may be classified as over-the-counter (OTC).

Q: Can people with diabetes use Vurdon?

Official documents often list cardiovascular risk factors, including diabetes, as conditions that require careful consideration before use. Regulatory guidance advises that people with these conditions use the lowest effective dose due to the risks associated with the NSAID class.

Q: Can Vurdon cause sleep issues or insomnia?

Official documentation cites common nervous system effects, and some product information lists related effects like somnolence (drowsiness) or other central nervous system disturbances. Patients are typically advised to monitor their reaction to the medicine.

Q: Is there a list of ingredients in Vurdon besides the active one?

Yes, official prescribing information (labeling) for each specific product formulation is required to include a list of all inactive ingredients (excipients). This information is often found in the 'Description' or 'Inactive Ingredients' section of the regulatory documents.

How should Vurdon  be stored and disposed of?

Storage Requirements

Official regulatory guidelines dictate that Vurdon (Diclofenac Sodium) must be stored at or below 30 C and must not be frozen. To maintain product integrity and stability, the medicine must be kept in its original package and outer carton to protect it from exposure to light and moisture. Always store this product out of the sight and reach of children.

Handling and Stability

Specific dosage forms, such as suppositories, require careful handling, including the instruction to not break the product. Depending on the strength, the official shelf life is documented as two or three years from manufacture.

Disposal Instructions

Unused or expired Vurdon should be disposed of using a drug take-back program where available. If a take-back program is unavailable, mix the medicine with an undesirable substance (like coffee grounds or dirt), place it in a sealed container, and discard it in the household trash. Do not flush Vurdon down the toilet or sink unless specific labeling instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vurdon  found in:

A-Z Index: